Study of EVO756 in Adults With Migraine
Trial details
- Registry ID
- NCT07616128
- Drugs studied
- EVO756, Dose 1, EVO756, Dose 2
TrialRedline tracks 6 clinical trials sponsored by Evommune, Inc.: 6 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of EVO756 in Adults With MigraineNCT07616128 | EVO756, Dose 1, EVO756, Dose 2 | Recruiting | 2027-10Estimated |
| Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845 | EVO756 | Completed | 2026-07-23Actual |
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)NCT06873516 | EVO756 | Completed | 2026-05-29Actual |
| Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisNCT06723405 | EVO301 | Completed | 2025-11-17Actual |
| A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible UrticariaNCT06603220 | Oral EVO756 300 mg QD, Oral EVO756 50 mg BID | Completed | 2025-05-08Actual |
| Safety and Efficacy Study of EVO101 Topical Cream in Atopic DermatitisNCT05579899 | EVO101 | Completed | 2023-07-27Actual |
Names as written in the registry records.
NCT07150845 · Evommune, Inc.
Before: Estimated. After: Actual.
Before: 120 participants (planned). After: 121 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2026. After: 23 Jul 2026.
Before: Active not recruiting. After: Completed.
NCT07616128 · Evommune, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT06873516 · Evommune, Inc.
Before: Estimated. After: Actual.
Before: 160 participants (planned). After: 182 participants (actual).
Before: Estimated. After: Actual.
Before: Jun 2026. After: 29 May 2026.
Before: Active not recruiting. After: Completed.
NCT07150845 · Evommune, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06873516 · Evommune, Inc.
Before: May 2026. After: Jun 2026.
NCT06603220 · Evommune, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability. After: Measure: Safety and Tolerability.
NCT06873516 · Evommune, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06723405 · Evommune, Inc.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 71 participants (actual).
Before: Estimated. After: Actual.
Before: Nov 2025. After: 17 Nov 2025.
Before: Active not recruiting. After: Completed.